Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of 7.38 billion. The enterprise value is 18.74 billion.
Market Cap | 7.38B |
Enterprise Value | 18.74B |
Important Dates
The last earnings date was Friday, April 25, 2025.
Earnings Date | Apr 25, 2025 |
Ex-Dividend Date | Jun 18, 2024 |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | +0.35% |
Shares Change (QoQ) | -0.66% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 1.34B |
Valuation Ratios
The trailing PE ratio is 7.56.
PE Ratio | 7.56 |
Forward PE | n/a |
PS Ratio | 0.09 |
PB Ratio | 0.41 |
P/TBV Ratio | 0.76 |
P/FCF Ratio | 2.29 |
P/OCF Ratio | 2.16 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.81, with an EV/FCF ratio of 5.80.
EV / Earnings | 19.19 |
EV / Sales | 0.23 |
EV / EBITDA | 5.81 |
EV / EBIT | 7.21 |
EV / FCF | 5.80 |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.61.
Current Ratio | 1.34 |
Quick Ratio | 1.07 |
Debt / Equity | 0.61 |
Debt / EBITDA | 3.56 |
Debt / FCF | 3.37 |
Interest Coverage | 6.65 |
Financial Efficiency
Return on equity (ROE) is 8.24% and return on invested capital (ROIC) is 5.47%.
Return on Equity (ROE) | 8.24% |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | 5.47% |
Return on Capital Employed (ROCE) | 12.48% |
Revenue Per Employee | 737,197 |
Profits Per Employee | 9,024 |
Employee Count | 108,217 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.37% in the last 52 weeks. The beta is 0.63, so Sinopharm Group's price volatility has been lower than the market average.
Beta (5Y) | 0.63 |
52-Week Price Change | -7.37% |
50-Day Moving Average | 11.98 |
200-Day Moving Average | 12.50 |
Relative Strength Index (RSI) | 51.44 |
Average Volume (20 Days) | 20,894 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of 79.78 billion and earned 976.57 million in profits. Earnings per share was 0.31.
Revenue | 79.78B |
Gross Profit | 6.00B |
Operating Income | 2.43B |
Pretax Income | 1.90B |
Net Income | 976.57M |
EBITDA | 2.72B |
EBIT | 2.43B |
Earnings Per Share (EPS) | 0.31 |
Balance Sheet
The company has 6.25 billion in cash and 10.87 billion in debt, giving a net cash position of -4.62 billion.
Cash & Cash Equivalents | 6.25B |
Total Debt | 10.87B |
Net Cash | -4.62B |
Net Cash Per Share | n/a |
Equity (Book Value) | 17.80B |
Book Value Per Share | 3.55 |
Working Capital | 13.00B |
Cash Flow
In the last 12 months, operating cash flow was 3.41 billion and capital expenditures -181.85 million, giving a free cash flow of 3.23 billion.
Operating Cash Flow | 3.41B |
Capital Expenditures | -181.85M |
Free Cash Flow | 3.23B |
FCF Per Share | n/a |
Margins
Gross margin is 7.53%, with operating and profit margins of 3.04% and 1.22%.
Gross Margin | 7.53% |
Operating Margin | 3.04% |
Pretax Margin | 2.39% |
Profit Margin | 1.22% |
EBITDA Margin | 3.41% |
EBIT Margin | 3.04% |
FCF Margin | 4.05% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 4.23%.
Dividend Per Share | 0.50 |
Dividend Yield | 4.23% |
Dividend Growth (YoY) | 7.35% |
Years of Dividend Growth | 4 |
Payout Ratio | 29.23% |
Buyback Yield | -0.35% |
Shareholder Yield | 3.88% |
Earnings Yield | 13.23% |
FCF Yield | 43.75% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Sinopharm Group has an Altman Z-Score of 2.12. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.12 |
Piotroski F-Score | n/a |